secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xilio Therapeutics, Inc. (XLO)
CIK:        0001840233
Form:       8-K
Filed at:   2023-12-07T23:59:59+00:00
Accession:  0001558370-23-019579
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xilio initiates Phase 1 combo trial of XTX101 with atezolizumab; reports updated monotherapy data with 33% DCR
--------------------------------------------------------------------------------

- Initiated enrollment for Phase 1 dose escalation of XTX101 in combination with atezolizumab; RP2D for combo expected Q2 2024.
- Updated monotherapy data at RP2D (150 mg Q6W) show 33% disease control rate in late-line/IO refractory patients; no discontinuations due to TRAE.
- Confirmed partial response in PD-L1 negative NSCLC patient continued through 36 weeks with complete resolution of liver metastases.
- Plans to initiate Phase 2 trial in MSS CRC in Q3 2024, subject to obtaining sufficient additional capital.
- Preliminary PK demonstrates tumor-selective activation: 96% in melanoma, 73% in liver metastasis vs 13% peripheral activation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840233/000155837023019579/0001558370-23-019579-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840233/000155837023019579/xlo-20231207x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-019579

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer